Metalloproteinases as biomarkers of chronic obstructive pulmonary disease progression
https://doi.org/10.18093/0869-0189-2022-2354
Abstract
According to the World Health Organization, chronic obstructive pulmonary disease is the third leading cause of death in 2020, accounting for approximately 6% of all deaths.
Aim. We studied how matrix metalloproteinases affect the likelihood and severity of chronic obstructive pulmonary disease.
Methods. The study included 60 patients aged 40 to 85 years with chronic obstructive pulmonary disease (7 women and 53 men). The average age of the patients was 63.2 ± 8.3 years. The smoker index ranged from 10 to 118 pack/years. We divided all examined patients into two groups by the severity of the disease, by age, by the duration of the disease, and by the clinical forms.
Results. Among the 60 examined patients, we did not identify a single patient with polymorphic variant C536T of TIMP-1 gene. All patients were homozygous and had the CC genotype. We found that only C-1562T polymorphism of MMP-9 gene is associated with severe COPD (p = 0.014), out of all studied variants of MMP-1, MMP-9, and MMP-12 genes. We did not find a reliable relationship between polymorphic variant C-1562T of MMP-9 gene and emphysematous changes in the lungs. We did not find a significant effect of polymorphic variants of MMP-1 and MMP-12 genes on the severity of COPD and the nature of structural changes in the lung tissue. As a result, we can assume that future studies should focus more on the relationship between the dominant pathogen and the level of matrix metalloproteinases. Understanding this relationship will allow us to influence the course and prognosis at an earlier stage of the disease. Our data on the leading role of polymorphism of MMP-1, MMP-9, and MMP-12 genes and other candidate genes are also confirmed by other recently published scientific papers.
Conclusion. This study established the presence of genetic markers for a poor prognosis of COPD. Smokers and people subject to occupational hazards are most susceptible to these factors.
Supporting agencies: There was no financial support for the study
About the Authors
O. A. Tsvetkova
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Olga A. Tsvetkova - Doctor of Medicine, Professor of the Department of Hospital Therapy No.1.
Ul. Trubetskaya 8, build. 2, Moscow, 119991; tel.: (499) 248-17-00
Competing Interests:
The authors declare that there is no conflict of interests.
O. O. Voronkova
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Olga O. Voronkova, Candidate of Medicine, Assistant Professor, Department of Hospital Therapy No.1.
Ul. Trubetskaya 8, build. 2, Moscow, 119991; tel.: (499) 248-17-00
Competing Interests:
The authors declare that there is no conflict of interests.
O. E. Buyanova
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Olga E. Buyanova - Pulmonologist, Department of Pulmonology, Hospital Therapy Clinic, University Clinical Hospital No.1.
Ul. Trubetskaya 8, build. 2, Moscow, 119991; tel.: (499) 248-17-00
Competing Interests:
The authors declare that there is no conflict of interests.
A. O. Dubinin
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Alexander O. Dubinin – Student.
Ul. Trubetskaya 8, build. 2, Moscow, 119991; tel.: (499) 248-17-00
Competing Interests:
The authors declare that there is no conflict of interests.
References
1. André S., Conde B., Fragoso E. et al. DPOC and cardiovascular disease. Pulmonology. 2019; 25 (3): 168–176. DOI: 10.1016/j.pulmoe.2018.09.006.
2. Faner R., Rojas M., Macnee W., Agustí A. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012; 186 (4): 306–313. DOI: 10.1164/rccm.201202-0282PP.
3. Ito K., Barnes P.J. COPD as a disease of accelerated lung aging. Chest. 2009; 135 (1): 173–180. DOI: 10.1378/chest.08-1419.
4. Wang Y., Xu J., Meng Y. et al. Role of inflammatory cells in airway remodeling in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3341–3348. DOI: 10.2147/COPD.S176122.
5. McGuinness A.J.A.; Sapey E. Oxidative stress in COPD: sources, markers, and potential mechanisms. J. Clin. Med. 2017; 6 (2): 21. DOI: 10.3390/jcm6020021.
6. Morris A., Kinnear G., Wan W. Y. et al. Comparison of cigarette smokeinduced acute inflammation in multiple strains of mice and the effect of a matrix metalloproteinase inhibitor on these responses. J. Pharmacol. Exp. Ther. 2008; 327 (3): 851–862. DOI: 10.1124/jpet.108.140848.
7. Duque G.A., Descoteaux A. Macrophage cytokines: involvement immunity and infectious diseases. Front. Immunol. 2014; 5: 491. DOI: 10.3389/fimmu.2014.00491.
8. Zhou H., Wu Y., Jin Y. et al. Genetic polymorphism of matrix metalloproteinase family and chronic obstructive pulmonary disease susceptibility: a meta-analysis. Sci. Rep. 2013; 3: 2818. DOI: 10.1038/srep02818.
9. Shadrina A.S., Plieva Ya.Z., Kushlinskiy D.N. et al. [Classification, regulation of activity, and genetic polymorphism of matrix metalloproteinases in health and disease]. Al’manakh klinicheskoy meditsiny. 2017; 45 (4): 266–279. DOI: 10.18786/2072-0505-2017-45-4-266-279 (in Russian).
10. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Menagement, and Prevention of Chronic Obstructive Pulmonary Disease. 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINALrevised-20-Nov_WMS.pdf
11. Hikichi М., Mizumura К., Maruoka S. , Gon Y. Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. J. Thorac. Dis. 2019; 11 (Suppl. 17): S2129–2140. DOI: 10.21037/jtd.2019.10.43.
12. Gharib S.A., Manicone A.M., Parks W.C. Matrix metalloproteinases in emphysema. Matrix Biol. 2018; 73: 34–51. DOI: 10.1016/j.matbio.2018.01.018.
13. Gnoevykh V.V., Gening T.P., Portnova Yu.A. et al. [Matrix metalloproteinases and clinical and functional status in smokers with persistent asthma]. Terapevticheskiy arkhiv. 2014; 86 (8): 29–34. Available at: https://www.mediasphera.ru/issues/terapevticheskij-arkhiv/2014/8/downloads/ru/030040-3660201485 (in Russian).
14. Li Y., Lu Y., Zhao Z. et al. Relationships of MMP-9 and TIMP-1 proteins with chronic obstructive pulmonary disease risk: a systematic review and meta-analysis. J. Res. Med. Sci. 2016; 21: 12. DOI: 10.4103/1735-1995.178737.
15. Grigorkevich O.S., Mokrov G.V., Kosova L.Yu. [Matrix metalloproteinases and their inhibitors]. Farmakokinetika i farmakodinamika. 2019; (2): 3–16. Available at: https://www.pharmacokinetica.ru/jour/article/view/87/87 (in Russian).
16. Mikheev A.V., Baskevich M.A. [The role of matrix metalloproteinases in pulmonary diseases development]. Nauka molodykh (Eruditio Juvenium). 2015; (1): 106–115. Available at: http://naukamolod.rzgmu.ru/uploads/art/art133_3f2853.pdf (in Russian).
17. Zhao R., Zhou H., Zhu J. MMP-9-C1562T polymorphism and susceptibility to chronic obstructive pulmonary disease: a metaanaly sis. Medicine (Baltimore). 2020; 99 (31): e21479. DOI: 10.1097/MD.0000000000021479.
18. Markelova E.V., Zdor V.V., Romanchuk A.L., Birko O.N. [Matrix metalloproteinases: relationship with cytokines system, diagnostic and prognostic potential]. Immunopatologiya, allergologiya, infektologiya. 2016; (2): 11–22. DOI: 10.14427/jipai.2016.2.11 (in Russian).
19. Stankovic M., Nikolic A., Nagorni-Obradovic L. et al. Gene– gene interactions between glutathione S-transferase M1 and matrix metalloproteinases 1, 9, and 12 in chronic obstructive pulmonary disease in Serbians. COPD. 2017; 14 (6): 581–589. DOI: 10.1080/15412555.2017.1369022.
20. Taylor S.L., Rogers G.B., Chen A.C. et al. Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. Ann. Am. Thorac. Soc. 2015; 12 (5): 701–707. DOI: 10.1513/AnnalsATS.201411-513OC.
Supplementary files
Review
For citations:
Tsvetkova O.A., Voronkova O.O., Buyanova O.E., Dubinin A.O. Metalloproteinases as biomarkers of chronic obstructive pulmonary disease progression. PULMONOLOGIYA. 2023;33(1):36-43. (In Russ.) https://doi.org/10.18093/0869-0189-2022-2354
Views:
726
Email this article 